Evidence map›Paper›PMID 42562610›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Sinuo Gao, Zhaoqi Zhang, Chao Shi, Cheng Cheng, Xindi Ma, Xinming Zhao, Yunjiang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sinuo GaoDepartment of Breast Center, Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Zhaoqi ZhangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China; and.
Chao ShiDepartment of Breast Center, Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Cheng ChengGeneral Surgery, The First Hospital of Qinhuangdao, Qinhuangdao, China.
Xindi MaDepartment of Breast Center, Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Xinming ZhaoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China; and lyj818326@hebmu.edu.cn xinmingzhao@hebmu.edu.cn.
Yunjiang LiuDepartment of Breast Center, Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China; lyj818326@hebmu.edu.cn xinmingzhao@hebmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the predictive performance of

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyPositron Emission Tomography Computed TomographyAdultAgedFemaleGallium RadioisotopesHumansMiddle AgedNeoplasm StagingPathologic Complete ResponsePreoperative PeriodProspective StudiesTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGallium-68Gallium Radioisotopes68Ga-HER2 PET/CTHER2-positive breast cancerNATpCR

Identifiers

PMID42562610
PMCPMC13635078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.